Healthcare

BridgeBio Oncology Therapeutics reported third-quarter 2026 progress across its RAS-pathway oncology pipeline. In a specified cohort of previously KRAS G12C inhibitor-treated non-small-cell lung cancer patients, BBO-8520 with pembrolizumab showed a 75% objective response rate at the 500 mg once-daily dose level.

Cumberland Pharmaceuticals announced plans to submit a new drug application for ifetroban as a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy. The decision was included in the company’s November 10 third-quarter update.

Yarrow Bioscience closed a USD 172.5 mn underwritten public offering in September 2026, including full exercise of the underwriters’ option to acquire additional shares.

Longeveron announced updated results from its ELPIS II Phase 2b trial in October 2026. The trial evaluates investigational laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare paediatric heart condition.

Electra Therapeutics announced initiation of a Phase 1 trial of ELA822 in September 2026. The investigational antibody targets SIRPγ and is designed for T-cell-mediated immune and inflammatory diseases.

The noteholder agreements cover approximately 95% of outstanding convertible note principal. Their conversion into common shares depends on completing a strategic merger and meeting additional conditions. The agreements are therefore a notable step in the planned financing structure, rather than an already completed elimination …

On September 30, 2026, Silexion announced successful dosing of the first patient in its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer. The event followed the company’s earlier initiation of the study and regulatory clearance work in Israel and Germany. First dosing …